Europe remains one of the most important pharmaceutical markets in the world, but successfully launching a therapy across the region has never been more complex.
In a recent article for the European Biopharmaceutical Review (EBR) Bio-Europe Supplement, Mike Ryan, President, Europe at EVERSANA, explores the challenges facing both emerging and established biopharma companies as they navigate market access, pricing, reimbursement, and commercialization across Europe’s fragmented healthcare landscape.
Read the full article on pages 28-30 of the BIO-Europe Supplement, Autumn 2026
Understanding Europe’s Fragmented Pharmaceutical Market
While companies often think about a “European launch,” the reality is far more complex.
Each country operates within its own healthcare system, reimbursement environment and evidence requirements. Manufacturers must also navigate national pricing negotiations, health technology assessments (HTAs), reimbursement pathways and local market dynamics.
As a result, Europe cannot be approached with a simple extension of a U.S. commercialization strategy.
Why Early Market Access Planning is Critical for European Launches
One of the most significant shifts highlighted by Ryan is the growing importance of integrating market access planning well before approval.
Today, clinical development, evidence generation and access strategy must work together from the outset. Decisions around trial design, comparators, endpoints and real-world evidence can have a significant impact on downstream HTA outcomes and reimbursement success.
Organizations that wait until approval to begin access planning risk slowing patient access and reducing long-term asset value.
Launching across Europe also requires navigating multiple markets, languages, supply chains and compliance requirements simultaneously.
Pricing decisions in one country can influence reimbursement and pricing outcomes in many others due to international reference pricing frameworks.
This makes launch sequencing, pricing governance and commercial execution critical components of a successful European strategy.
Alternative Commercialization Models for Biopharma in Europe
According to Ryan, biopharma companies no longer need to choose between building costly local infrastructure and sacrificing long-term value through traditional licensing models.
Instead, many organizations are adopting more integrated commercialization approaches that allow them to preserve strategic control, reduce risk and accelerate time-to-revenue while maintaining flexibility.
As Europe’s healthcare landscape continues to evolve, success will increasingly depend on treating regulatory strategy, evidence generation, market access and commercialization as a connected ecosystem rather than separate functions.
Schedule a meeting with our team at BIO Europe 2026
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…